Anmeldung erfolgt in Kürze...
Details werden geladen...
Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant) | The Manila Times
LOUISVILLE, Ky., July 29, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Rigel Pharmaceuticals for VEPPANU™ (vepdegestrant), which is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.1
Ähnliche Seiten
Onco360® Has Been Selected as a National Specialty Pharmacy Provider for IMKELDI® (imatinib) Oral Solution | The Manila Times
https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/onco360-has-been-selected-as-a-national-specialty-pharmacy-provider-for-imkeldi-imatinib-oral-solution/2357326
Vibrant Gastro™ Selects MedOptions Rx as Exclusive Specialty Pharmacy Partner to Enhance Patient Access to the Vibrant System® | The Manila Times
https://www.manilatimes.net/2026/07/14/tmt-newswire/globenewswire/vibrant-gastro-selects-medoptions-rx-as-exclusive-specialty-pharmacy-partner-to-enhance-patient-access-to-the-vibrant-system/2384193Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer | ...
https://www.manilatimes.net/2026/07/30/tmt-newswire/globenewswire/newly-fda-approved-revtorpyk-gedatolisib-included-in-the-national-comprehensive-cancer-network-nccn-clinical-practice-guidelines-for-hrher2-locally-advanced-or-metastatic-breast-cancer/2395073BrightPlan Selected as Eminence Partner by Brandon Hall Group™ | The Manila Times
https://www.manilatimes.net/2026/06/17/tmt-newswire/globenewswire/brightplan-selected-as-eminence-partner-by-brandon-hall-group/2367630Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome | The Manila Times
https://www.manilatimes.net/2026/06/23/tmt-newswire/globenewswire/quoin-pharmaceuticals-receives-fda-conditional-approval-of-qyleki-as-the-proposed-brand-name-for-qrx003-for-netherton-syndrome/2370972